MedTrace Logo

The Effects of Preoperative Bevacizumab on Perioperative Complications

NCT04788381 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-03-09

No results posted yet for this study

Summary

This is a nationwide multicenter,retrospective,observational real-world study.

1. To assess the risk of perioperative complications in patients with tumor who received bevacizumab prior to unexpected operation.
2. To assess the correlation of the interval time between the last dose of bevacizumab and operation and occurrence of perioperative complications.
3. To explore the risk factors of perioperative comlications in patients with tumor received bevacizumab prior to unexpected operation.

Conditions

Interventions

DRUG

Bevacizumab

Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Su Zhan Zhang · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-05-31
Completion
2021-07-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788381 on ClinicalTrials.gov